Sales Slip at McKesson

Zacks

McKesson Corporation’s (MCK) second quarter fiscal 2013 (ended September 30, 2012) adjusted earnings of $1.92 per share surpassed the Zacks Consensus Estimate of $1.76 per share. Also, the reported quarter’s adjusted earnings spiked 18% from the year-ago period. Earnings benefited from a lower share count.

Revenues declined 1% to $29.9 billion. Revenues were short of the Zacks Consensus Estimate of $30.9 billion.

Quarter in Detail

McKesson operates through two segments: Distribution Solutions and Technology Solutions.

Revenues at the Distribution Solutions segment decreased 1% to $29 billion in the reported quarter. The decline was attributable to lower sales in the US pharmaceutical distribution unit.

Revenues from the US pharmaceutical distribution business came in at $25.7 billion, down 1%. The decline was due to brand-to-generic conversions and one less sales day.    

Canadian revenue decreased 5% to $2.4 billion. The decrease was attributable to unfavorable foreign exchange movements. Revenues from Medical-Surgical distribution and services came in flat at $873 million. Sales of the sub-group were impacted by fewer sales days in the quarter.

Revenues at the Technology Solutions segment came in flat at $824 million. Operating expenses climbed 1.9% in the reported quarter to $1.1 billion.

Fiscal 2013 Outlook

The company tweaked its adjusted earnings outlook for fiscal 2013. McKesson expects earnings (excluding special items) in the range of $7.15-$7.35 per share (previous projection: $7.05 - $7.35 share). The Zacks Consensus Estimate for fiscal 2013 currently stands at $7.26 per share.

McKesson to Buy PSS World

In a bid to expand its product portfolio, McKesson inked a deal to buy PSS World Medical, Inc. (PSSI) for $29.00 per share in cash. The total value of the deal, in which McKesson will assume PSS World Medical’s debt, is estimated at approximately $2.1 billion. McKesson expects to generate more than $100 million in annual savings (pre-tax) by the fourth year after the closure of the deal.

Neutral on McKesson

We currently have a Neutral recommendation on McKesson. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Read the Full Research Report on MCK

Read the Full Research Report on PSSI

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)